Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Suzhou Zanrong Completes $20 Million A+ Round for Cancer Drugs

publication date: Aug 10, 2020

Suzhou Zanrong Pharma completed a $20 million Series A+ financing to develop small molecule drugs for cancer indications. It has one candidate approved to start clinical trials and others in pre-clinical development. Suzhou Zanrong was founded in 2019, one year after Shanghai Zanrong was formed. Both companies are affiliated with Zion Pharma of Hong Kong, sharing management and scientific teams. The financing was led by Sherpa Venture Capital and Qiming Venture with participation from Med-Fine Capital. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital